Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects - Wikidata - wikimedia - TriplyDB

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

http://www.wikidata.org/entity/Q34792580

about

Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.Validation of the effects of TGF-β1 on tumor recurrence and prognosis through tumor retrieval and cell mechanical properties MDSC and TGFß are required for facilitation of tumor growth in the lungs of mice exposed to carbon nanotubes Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function Interaction with Smad4 is indispensable for suppression of BMP signaling by c-Ski 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo Autocrine PDGFR signaling promotes mammary cancer metastasis Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction Genetic engineering with T cell receptors Targeting TGF-β signaling in cancer Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy Complexities of TGF-β targeted cancer therapy.Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1)Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy Stromal fibroblasts in cancer initiation and progression A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy Expression profiling of genes regulated by TGF-beta: differential regulation in normal and tumour cells.Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor.An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.Two faces of TGF-beta1 in breast cancer.TGF-beta biology in mammary development and breast cancer.Transforming growth factor beta (TGF-beta) and inflammation in cancer.Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer.The G protein-coupled receptor kinase-2 is a TGFbeta-inducible antagonist of TGFbeta signal transduction.Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-beta1-mediated tissue fibrosis.Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model Tgf-beta signaling pathway in lung adenocarcinoma invasion.A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer.Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.Efficient TGF-β/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression.Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.

P2860

Q21142766-963868BF-8617-4EE3-BC00-4819F85E770C Q21246016-7F34895B-7B9A-4193-8ADD-F6532CE34BBC Q23909988-5516DB90-6862-4B1D-BB64-C91E98B0D116 Q24302428-F5CF6D80-AFF8-4391-97C7-AFF0965D27A8 Q24303530-EC38C346-81CF-4100-B839-E902F1D89095 Q24313042-E4904BBE-7360-41E5-82CE-6E537161D95F Q24316195-6E1B18C5-4182-4FD2-9634-57B0D413B5C8 Q24545375-91F13BC1-4CB9-41C5-9085-1DDA581515D0 Q24679619-C91A1B93-683D-4041-918E-01E1B7FF98DB Q24806331-1B0AEE86-F908-400E-A7A0-BE2577AC6A66 Q26797238-50EE8C0D-3DEF-494E-851F-8D03C84B4A42 Q26801834-D824BD33-9A55-4CFE-8EAC-9135B6E82BD1 Q26995677-5FEA7509-1238-4800-92B7-73A3AF21A8BE Q27012443-2082A920-F6A1-41CC-980D-CFA9809C1C4B Q27021750-2A410D81-7791-4B01-907F-AF9E21EA2731 Q27693607-B3D8CCF7-693B-4E95-9262-22027BCC5EBC Q28303698-FEB30E9F-9434-48B3-A173-FEC77FC9F528 Q28583200-F50794AA-2AF6-450C-A0E9-CBC17E743705 Q28584353-2B86FA5D-5DAB-427B-9E70-1F724A489E93 Q28742851-48D14E33-5214-46DA-ACA5-D5CDD849DC86 Q29010479-3D94B098-5C26-42CD-8440-F57D7371ECE7 Q29618873-1CFABB24-E7FA-4F4D-85E6-B831A88CD56B Q30434613-84B2D6F6-0706-4597-BD9A-A48CB70EE564 Q33281716-584B7F44-A2EB-4520-91A0-740014DF6994 Q33570741-035F8154-C26E-4A04-9002-48C8D2151AA5 Q33615675-E3E8C185-32D8-424B-BB2E-5D9CADCD7FE5 Q33631922-1A3B393A-6B75-4019-9C35-50FB02934E90 Q33637647-EF74CB62-1291-4AC4-AD93-432112842970 Q33661529-77A447D6-26D6-4107-8110-760BE40319CE Q33681686-CD7B73A5-611F-468B-AE69-5FBA16DD7F0C Q33712568-29292CF7-06A2-44CA-888B-B6011859F416 Q33912255-1818ABE5-E8DE-4AFE-92DA-C5F15D798BC4 Q34016197-68FF2FE0-6030-43B0-A441-46CA03316633 Q34149752-FE97AB3A-40E2-471E-8489-7C71248784CE Q34298885-8263D0D5-688A-4E0C-9AE2-CD892531C861 Q34356297-CAFD78A9-0FCE-4637-B134-9B070A57190D Q34432864-532A468B-F570-49E8-B59D-13BB2498AA53 Q34487585-7824CC62-1C1F-4D5C-9A47-3BC093078A6E Q34516142-0F444C83-A039-4417-8420-87C782F6B48C Q34521619-709F8D39-F215-424F-8FC2-EDF7325B87AC

P2860

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

http://www.wikidata.org/entity/Q34792580

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Lifetime exposure to a soluble ...... s without adverse side effects

@ast

Lifetime exposure to a soluble ...... s without adverse side effects

@en

Lifetime exposure to a soluble ...... s without adverse side effects

@nl

type

label

Lifetime exposure to a soluble ...... s without adverse side effects

@ast

Lifetime exposure to a soluble ...... s without adverse side effects

@en

Lifetime exposure to a soluble ...... s without adverse side effects

@nl

prefLabel

Lifetime exposure to a soluble ...... s without adverse side effects

@ast

Lifetime exposure to a soluble ...... s without adverse side effects

@en

Lifetime exposure to a soluble ...... s without adverse side effects

@nl

P1433

Q34792580-806B0CA0-A83C-42F9-B2F3-9DDB2416BA5A

P1476

Q34792580-2A2684AB-19B7-49DB-882D-53B3BF9C7317

P2093

Q34792580-07785955-E638-48C4-AFDD-F4C8E549F2DE

Q34792580-250B059C-125F-4C3C-821A-BD62087145EF

Q34792580-32945B65-D493-4262-9077-10FA49E841F0

Q34792580-7FF60D24-07AB-446A-BB84-3BE1D8B39BA6

Q34792580-98F8C7DC-D63B-4AB6-90A9-9167F15F9809

Q34792580-A6D68CE8-9CAD-4157-98C6-B02BCAA91409

Q34792580-C340CE16-5A9E-4256-AFEE-6B074D230020

Q34792580-DD0D1DFF-9524-4D88-B4D9-9FE54BCEE3CF

Q34792580-E5714DDE-E5F4-4780-8660-E7FDD78C655C

Q34792580-EFF2721F-BFC0-4668-A502-0E0E60367FAC

P2860

Q34792580-0398F9E0-FF2F-4268-8686-3A81DE61673A

Q34792580-053FABB1-4038-4326-BF4F-9CE64B1E3A29

Q34792580-1A98C66C-E767-476A-AC95-FEF0DD858DA2

Q34792580-1ABBF814-5FCC-4B70-9519-036AFA662D82

Q34792580-1AFA49DC-6034-4989-B8A9-2DD5C2E7AC49

Q34792580-2B47D1FF-64BA-4E5A-B67F-15D67CAAC252

Q34792580-2CB160E1-AE57-4E0D-9E18-CF1008D29F9B

Q34792580-2F6E7976-910B-4A0F-96F3-7D86D9166A50

Q34792580-2F949D70-3CF0-4185-82BB-87F01EF79C92

Q34792580-4063A0BC-04F3-4157-B1C7-5F15311830D1

P304

Q34792580-7764CCBC-86F1-4E45-B857-037B49E03B69

P31

Q34792580-024F35FE-6EF0-4EAA-9305-376D3F7BA16D

P356

Q34792580-420792C7-286F-4C3C-BDE7-5BF2C97F948D

Q34792580-52A45BDA-04B8-45BB-BA6E-F797DB500D3D

P407

Q34792580-6C3EFEF8-6126-4EC7-AB66-C45EB5A74A8D

P433

Q34792580-42FD63FB-D219-464E-9BA8-B77D44B4D8D7

P478

Q34792580-975704C9-46C7-4133-9FB8-40E1A53F515F

P50

Q34792580-0DB95684-1C17-403C-B529-40A2D8D472F6

Q34792580-156BFD5A-2AD7-4614-8D6B-B0AFAB2358B3

Q34792580-A1BC1CB7-0E62-430B-AFBC-CF92775AED10

P577

Q34792580-D56389CD-963E-4255-9AFA-78289100B940

P698

Q34792580-AFC6965E-D340-4921-AE91-754CEBDD7CE2

P932

Q34792580-98D375C0-5F9E-425A-8796-DA38413D6FF0

P356

P1433

Journal of Clinical Investigation

P1476

Lifetime exposure to a soluble ...... s without adverse side effects

@en

P2093

Binwu Tang

http://www.w3.org/2001/XMLSchema#string

Glenn Merlino

http://www.w3.org/2001/XMLSchema#string

Jeffrey Green

http://www.w3.org/2001/XMLSchema#string

Jennifer MacGregor

http://www.w3.org/2001/XMLSchema#string

John J Letterio

http://www.w3.org/2001/XMLSchema#string

Miriam R Anver

http://www.w3.org/2001/XMLSchema#string

Oksana Dukhanina

http://www.w3.org/2001/XMLSchema#string

Sejal C Patel

http://www.w3.org/2001/XMLSchema#string

Yu-An Yang

http://www.w3.org/2001/XMLSchema#string

Zi-Yao Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death

Transforming growth factor-beta and breast cancer: Mammary gland development.

TGFbeta signaling in growth control, cancer, and heritable disorders

Role of transforming growth factor-beta signaling in cancer

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

Latent transforming growth factor-beta: structural features and mechanisms of activation

Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

TGF-beta signaling in tumor suppression and cancer progression

Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.

P304

1607-1615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI15333

http://www.w3.org/2001/XMLSchema#string

10.1172/JCI200215333

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Lalage M Wakefield

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12070308

http://www.w3.org/2001/XMLSchema#string

P932

151015

http://www.w3.org/2001/XMLSchema#string